Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 11179476
    Abstract: The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 23, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Shek Hang Benedict Law, Ching-Hsuan Tung, Vanessa Bellat
  • Patent number: 11180534
    Abstract: The present application relates to methods and compositions and methods for treating viral infections, especially those caused by SARS-CoV-2. In one aspect, a method of treatment comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a multipartite SARS-CoV-2-inhibiting peptide comprising a secretion modulating region (VI-SMR) peptide from HIV-1 Nef in combination with a cell-penetrating peptide (CPP) domain, a Clusterin (Clu)-binding peptide (Clu-BP) domain, a mitochondrial targeting (Mito-T) peptide domain, an anti-fusogenic (AF) peptide domain, a viral attachment inhibitor (VAI) domain or combination thereof, optionally where the SARS-CoV-2-inhibiting peptide is pegylated and/or modified with one or more hydrophobic domains.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: November 23, 2021
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent C. Bond, Ming Bo Huang, James W. Lillard, Jr.
  • Patent number: 11180533
    Abstract: The present invention relates to an improved process for the preparation of Cetrorelix acetate (1). More particularly, the present invention relates to the purification of Cetrorelix acetate (1) by simple method.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 23, 2021
    Assignee: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED
    Inventors: Manik Reddy Pullagurla, Jagadeesh Babu Rangisetty
  • Patent number: 11173189
    Abstract: In an aspect, a method of manufacture of a pharmaceutically acceptable solid composition containing daptomycin includes drying an aqueous solution containing (i) water, (ii) the daptomycin, (iii) sorbitol in an amount of about 1.2 wt. % to about 9.0 wt. % of total volume of the aqueous composition and (iv) mannitol in an amount of about 0.6 wt. % to about 9.5 wt. % of total volume of the aqueous composition to form the solid composition. The drying can include an sublimation drying of about ?25° C. to about 50° C. for a time period of about 15 hours to about 120 hours, most preferably about 15° C. for about 20 hours, optionally preceded and/or followed by one or more additional drying steps. Other aspects are the solid composition containing the daptomycin and also methods of treating a bacterial infection including administering a pharmaceutically acceptable product made by reconstituting the solid composition.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: November 16, 2021
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Lindsay Wegiel, Reagan Miller
  • Patent number: 11161886
    Abstract: The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: November 2, 2021
    Assignee: NOMAD BIOSCIENCE GMBH
    Inventors: Simone Hahn, Tobias Schneider, Anett Stephan, Steve Schulz, Anatoli Giritch, Yuri Gleba
  • Patent number: 11155800
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: October 26, 2021
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Philip Stewart Low, Venkatesh Chelvam, Youngsoon Kim, Sumith A. Kularatne
  • Patent number: 11155584
    Abstract: Described herein are unstructured polypeptides lacking any discernible repeat motif. Also described herein are fusion proteins including at least one of the unstructured polypeptides and at least one binding polypeptide. Further described are methods for treating a disease in a subject in need thereof. The methods may include administering to the subject an effective amount of the fusion protein.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 26, 2021
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Nicholas Tang, Garrett Kelly
  • Patent number: 11141457
    Abstract: This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: October 12, 2021
    Assignee: AMRYT ENDO, INC.
    Inventors: Asi Haviv, Ruth Engle Stevens, Jennings Ray Dawkins
  • Patent number: 11136361
    Abstract: [Problem to be Solved] The object of the present invention is to develop a method of regulating a target RNA. [Solution] There is provided a fusion protein comprising a functional domain which improves the protein expression level from mRNA and a PPR protein which can bind to a target mRNA in an RNA base-selective or RNA base sequence-specific manner.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 5, 2021
    Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Takahiro Nakamura, Yusuke Yagi
  • Patent number: 11129878
    Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: September 28, 2021
    Assignee: AMPIO PHARMACEUTICALS, INC.
    Inventors: David Bar-Or, Holli Cherevka
  • Patent number: 11130782
    Abstract: The present invention relates to novel peptide antagonists that inhibit binding of acetylcholine to the active site of the muscle-type nicotinic acetylcholine receptor. The peptide antagonists of the invention are useful in cosmetic compositions that prevent or improve the appearance of skin wrinkles and related skin conditions. The invention further relates to cosmetic and pharmaceutical compositions comprising a peptide antagonist of the invention, and methods for their use.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: September 28, 2021
    Inventor: Robert A. Love
  • Patent number: 11130816
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 28, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Patent number: 11124547
    Abstract: Computational systems and methods are described for identifying new type-ll bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-ll bacteriocin peptides are tested experimentally and show potent microbicidal activities. Further provided are the sequences of Newly identified type-ll bacteriocin peptides, and a method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a peptide comprising an amino acid sequence disclosed.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: September 21, 2021
    Assignee: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
    Inventors: Nannette Y. Yount, Michael R. Yeaman
  • Patent number: 11124558
    Abstract: A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 21, 2021
    Assignee: The Feinstein Institutes for Medical Research
    Inventors: Haichao Wang, Wei Li, Jianhua Li, Kevin J. Tracey
  • Patent number: 11119054
    Abstract: Provided are processes and materials for solving biological or structural information about proteins or other organic molecules. The processes capitalize on a rigid multimeric nanocage formed from self-assembling substructure proteins. The processes and materials allow for recognition and tight, optionally covalent, bonding of any protein molecule with a tag complementary to a capture sequence on the nanocage. The processes and materials may be used to obtain biological or structural information by cryo-electron microscopy and overcome prior limitations of target protein size or salt concentration.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 14, 2021
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Scott Eugene Lindner, Susan Hafenstein
  • Patent number: 11110147
    Abstract: The invention generally relates to pharmaceuticals and/or nutraceuticals. More particularly, the invention provides compositions of collagen-based peptides and specific digestive tract microbes useful for supporting or promoting joint, skin and/or bone health, and methods of preparation and use thereof. The invention further provides for the use of compositions of collagen-based peptides as a prebiotic for modulating the gut microbiome.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 7, 2021
    Assignees: UNIVERSITY OF ROCHESTER
    Inventors: Michael Zuscik, Janne Prawitt, Eric Schott, Robert Mooney, Christopher Farnsworth
  • Patent number: 11111285
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • Patent number: 11091517
    Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 17, 2021
    Assignees: TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, INC.
    Inventors: Toyomasa Katagiri, Tetsuro Yoshimaru, Takashi Miyamoto, Yasuhide Okamoto
  • Patent number: 11077167
    Abstract: The present invention provides an agent for promoting skeletal muscle injury repair which agent comprises at least one peptide selected from the following (1) to (4): (1) a peptide consisting of the amino acid sequence of SEQ ID NO: 1, (2) a peptide consisting of the amino acid sequence of SEQ ID NO: 2, (3) a peptide consisting of the amino acid sequence of SEQ ID NO: 3, and (4) a peptide which is a human osteopontin fragment and has the amino acid sequence of SEQ ID NO: 1, 2, or 3 at the C-terminus, or a salt thereof as an active ingredient.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: August 3, 2021
    Assignee: OSAKA UNIVERSITY
    Inventors: Susumu Tanaka, Mikihiko Kogo, Hirofumi Yamamoto, Naomasa Kawaguchi, Yoshinosuke Hamada
  • Patent number: 11071772
    Abstract: The present invention relates to a method for preventing and treating tissue and organ fibrosis, comprising administering an effective amount of plasminogen to a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: July 27, 2021
    Assignee: Talengen International Limited
    Inventor: Jinan Li